The Inactivated Hepatitis A vaccine (Adsorbed) I.P. is a sterile, ready to use suspension containing inactivated Hepatitis A virus (strain HM175), propagated in MRC-5 human diploid cells and adsorbed on aluminum hydroxide. The vaccine appears as off-white suspension which settles down on standing into two phases of colorless upper layer and white settled lower layer.
Havisure Children’s Product Detail
Composition:
Each 1 mL contains:
- Inactivated Hepatitis A antigen NLT 25 IU
- Aluminium content as Al(OH) NMT 1.25 mg
- Tween 20 ≤ 0.006 % w/v
- Phosphate buffer saline q.s.
Therapeutic Indications:
For prevention of Hepatitis A infection in children above 1 year.Dosage form and strength:
Liquid suspension for intramuscular injection.
- l 1.0 ml vial (single adult dose/ two pediatric doses)…
As per clinical trials:
100% seroconversion and seroprotection and significant rise in antibody titre level were observed in Post vaccination Group A subjects 19-49 years and Group B subjects 12 months to below 19 years of age*
https://www.sciencedirect.com/science/article/abs/pii/S0264410X23010502?via%3Dihub
The Inactivated Hepatitis A vaccine (Adsorbed) I.P. is a sterile, ready to use suspension containing inactivated Hepatitis A virus (strain HM175), propagated in MRC-5 human diploid cells and adsorbed on aluminum hydroxide. The vaccine appears as off-white suspension which settles down on standing into two phases of colorless upper layer and white settled lower layer.
Havisure Adult’s Product Detail
Composition:
Each 1 mL contains:
- Inactivated Hepatitis A antigen NLT 25 IU
- Aluminium content as Al(OH) NMT 1.25 mg
- Tween 20 ≤ 0.006 % w/v
- Phosphate buffer saline q.s.
Therapeutic Indications:
For prevention of Hepatitis A infection in adolescents and adults (19 years to 49 years of age)Dosage form and strength:
Liquid suspension for intramuscular injection.
- l 1.0 ml vial (single adult dose/ two pediatric doses)…
As per clinical trials:
100% seroconversion and seroprotection and significant rise in antibody titre level were observed in Post vaccination Group A subjects 19-49 years and Group B subjects 12 months to below 19 years of age*
https://www.sciencedirect.com/science/article/abs/pii/S0264410X23010502?via%3Dihub